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Abstract
Background: Ets1 is an oncogene that functions as a transcription factor and regulates the activity of many genes
potentially important for tumor initiation and progression. Interestingly, the Ets1 oncogene is over-expressed in many
human squamous cell cancers and over-expression is highly correlated with invasion and metastasis. Thus, Ets1 is believed
to mainly play a role in later stages of the oncogenic process, but not early events.
Methodology/Principal Findings: To better define the role of Ets1 in squamous cell carcinogenesis, we generated a
transgenic mouse model in which expression of the Ets1 oncogene could be temporally and spatially regulated. Upon Ets1
induction in differentiating cells of stratified squamous epithelium, these mice exhibited dramatic changes in epithelial
organization including increased proliferation and blocked terminal differentiation. The phenotype was completely reversed
when Ets1 expression was suppressed. In mice where Ets1 expression was re-induced at a later age, the phenotype was
more localized and the lesions that developed were more invasive. Many potential Ets1 targets were upregulated in the skin
of these mice with the most dramatic being the metalloprotease MMP13, which we demonstrate to be a direct
transcriptional target of Ets1.
Conclusions/Significance: Collectively, our data reveal that upregulation of Ets1 can be an early event that promotes pre-
neoplastic changes in epidermal tissues via its regulation of key genes driving growth and invasion. Thus, the Ets1
oncogene may be important for oncogenic processes in both early and late stages of tumor development.
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Introduction
The stratified squamous epithelium of the skin forms a barrier
between the underlying tissues and the outer milieu to prevent the
passage of water and other substances between these compart-
ments. Keratinocytes are the principal cell type found in stratified
squamous epithelia and generate biomolecules that are necessary
for the stability and resistance of the epithelial layer to mechanical
stress. The innermost layer of this stratified epithelium, known as
the basal layer (stratum basale), consists of a proliferative
compartment of undifferentiated cells. Basal cells periodically
withdraw from the cell cycle, detach from the basement
membrane and migrate outwards to enter the suprabasal
compartment. Differentiation of keratinocytes can be monitored
by the morphological appearance of the cells and by the
expression of particular marker proteins. Based on these criteria,
the differentiated layers of the epidermis can be visualized as three
separate regions: the spinous or prickle cell layer (stratum
spinosum), the granular layer (stratum granulosum) and the
cornified layer (stratum corneum).
Squamous cell carcinoma (SCC) is a malignant tumor of skin
keratinocytes that frequently arises in response to excessive sun
exposure or to chronic irritation. Numerous mouse models of
squamous cell cancer have been developed including carcinogen-
induced SCC, ultraviolet (UV) light-induced SCC and spontane-
ous SCC in various transgenic and knockout mouse strains.
Several common genetic alterations have been detected in
squamous cell tumors, including upregulation of oncogenes and
mutation of tumor suppressor genes [1,2]. In addition, several
recent studies have reported upregulation of the Ets1 proto-
oncogene in human SCC arising in skin [3] and other stratified
epithelia [4,5,6,7,8]. Moreover, upregulation of Ets1 expression
has also been detected in animal models of oral SCC [9,10].
Expression of high levels of Ets1 is correlated with increased
invasiveness and metastatic potential in both human SCC and
animal models of SCC.
Ets1 is a transcription factor that regulates the expression of
many key genes that are involved in cell growth, survival and
invasion. Importantly, Ets1 is thought to regulate the expression of
proteases such as urokinase plasminogen activator (uPA) and
various members of the matrix metalloprotease family (MMP1,
MMP2, MMP3, MMP9 and MMP13) [11,12,13,14,15,16]. Ex-
pression of these proteases is likely required for tumor cells to
degrade the surrounding extracellular matrix, invade nearby
tissues and eventually metastasize to distant sites. In addition, to
these proteases, Ets1 is also implicated in upregulation of a wide-
variety of genes that may promote tumorigenesis including genes
that control cellular proliferation or survival (bax, bcl-2, caspase-1, c-
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[17,18,19,20,21,22,23,24,25,26,27,28] and genes involved in
responses to a hypoxic environment [29]. Furthermore, Ets1 has
been reported to directly interact with the tumor suppressor
protein p53 and modulate its transcriptional activity
[30,31,32,33,34].
Because Ets1 regulates the expression of a large cohort of target
genes that influence cellular proliferation and survival, Ets1 might
play an important role in early stages of the carcinogenic process
in addition to its better known role in tumor invasion and
metastasis. To investigate the ability of Ets1 to drive neoplastic or
pre-neoplastic changes in stratified squamous epithelial cells, we
developed a transgenic mouse model that allows us to inducibly
express high levels of Ets1 protein in skin epithelium. Using this
inducible model system, we have explored the role of Ets1 in SCC.
Results
Ets1 is expressed predominantly in the proliferative basal
layer of the stratified squamous epithelium
Although Ets1 has previously been reported to be expressed in
embryonic mouse skin [35], the exact expression pattern of this
transcription factor during epidermal keratinocyte differentiation
has not been determined. We performed immunostaining for Ets1
protein in the skin epithelium of newborn and adult mice, which
showed that expression of Ets1 is predominantly restricted to the
nuclei of proliferative basal layer keratinocytes of the epidermis
and hair follicles of newborn mice (Fig. 1A). In contrast, more
differentiated suprabasal cells expressed little or no Ets1 protein. A
similar pattern of expression was detected in adult mice, with the
majority of Ets1 positive cells being localized to the basal layer and
to the hair follicles (Fig. 1A). We conclude that in mice Ets1 is
mainly expressed in undifferentiated keratinocytes of the skin and
its expression is downregulated as cells commit to the terminal
differentiation program. A similar pattern of expression of Ets1 in
basal cells, but not suprabasal differentiated cells, has been
detected in human skin samples [3].
Development of an inducible Ets1 transgenic model
As discussed in the Introduction, high levels of Ets1 expression
have been detected in SCC in humans and rodents. These
observations along with the expression pattern of Ets1 in the
proliferative compartment of the skin suggest that Ets1 may play a
role in keratinocyte proliferation. However, Ets1 knockout mice do
not display any obvious defects in the proliferation or differenti-
ation of skin keratinocytes, although they are characterized by a
Figure 1. Development of an inducible transgenic model to express Ets1 in differentiated epidermal keratinocytes. (A) Immuno-
histochemical localization of Ets1 in the nuclei of epidermal keratinocytes in newborn and adult mice. (B) Schematic representation of the
tetracycline-inducible Ets1 transgenic system. The system consists of two separate transgenes- the Tet driver transgene in which the tetracycline-
regulated transactivator protein (tTA) is under the control of the involucrin promoter and enhancer elements and the Tet responder transgene in
which an HA-tagged version of murine Ets1 is under the control of the pTight promoter containing tet-responsive elements (TRE, which are tTA
binding sites). When Tet driver and Tet responder mice are crossed, BT offspring are produced. Maintaining these BT animals on Dox
supplementation inhibits transgene expression, whereas withdrawal of Dox supplementation causes induced expression of the Ets1 transgene in cells
that normally express involucrin (upper spinous and granular layers). (C) Western blot analysis of transgene expression in skin extracts from newborn
wild-type and BT mice using anti-Ets1 and anti-HA antibodies. GAPDH serves as a loading control. (D) Immuno-histochemical localization of transgene
expression using antibody against the HA epitope tag.
doi:10.1371/journal.pone.0004179.g001
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in melanocyte proliferation, survival or migration (Fig S1A–C).
The lack of an obvious keratinocyte phenotype in Ets1 knockout
mice may be due to functional compensation by other Ets family
members, a number of which are expressed in skin. Indeed, the
closely related Ets2 protein is highly expressed in skin and has been
shown to play a role in hair follicle morphogenesis [36].
Although Ets1 is not essential for epidermal homeostasis under
physiological conditions, it may contribute to oncogenic transfor-
mation of these cells by promoting proliferation, epithelio-
mesenchymal transition (EMT) and/or invasion and metastasis.
In order to study the function of the Ets1 oncogene in skin
carcinogenesis, we developed a Tet-inducible Ets1 transgenic
mouse model. The full-length murine Ets1 cDNA was cloned in-
frame with an N-terminal HA epitope tag and inserted
downstream of the doxycycline-regulated pTight promoter in the
vector pTRE-Tight to generate the construct pTight-Ets1
(Figure 1B). The pTight-Ets1 construct was micro-injected into
fertilized mouse oocytes and six transgenic founders were
obtained. To test the ability of the six transgenic lines to inducibly
express Ets1, we crossed each founder with previously-described
transgenic mice expressing the tetracycline-transactivator (tTA)
under the control of the human involucrin promoter and enhancer
elements (INV-tTA mice) [37]. In the resulting bitransgenic (BT)
offspring (pTight-Ets1/ INV-tTA), HA-Ets1 can be induced in the
upper spinous and granular layers of skin and other stratified
squamous epithelial tissues when doxycyline (Dox) is withheld.
Note that this induced Ets1 expression pattern is opposite to the
normal pattern of Ets1 gene expression in the basal layer of the
epidermis.
When Ets1 expression was induced during embryonic develop-
ment by withholding Dox, BT newborn animals derived from two
of the six pTight-Ets1 founder animals, line C and E exhibited a
dramatic skin phenotype leading to a defect in epidermal barrier
formation and neonatal lethality (data not shown). In agreement
with the skin phenotype, line C and E were shown to express the
HA-Ets1 transgene by Western blotting (Figure 1C and data not
shown). The majority of the studies reported herein were
performed using the transgenic line C, but similar results were
obtained with line E.
To determine whether the transgene was faithfully expressed in
the differentiated layers of the epidermis, immunohistochemical
analysis using anti-HA antibodies was carried out. As shown in
Figure 1D, HA staining was evident in the differentiated layers of
the skin epithelium, but not in the undifferentiated basal layers.
The Ets1 transgene would also be expressed in differentiated cells
of the oral mucosa and other internal, stratified epithelia (i.e.,
esophagus, forestomach and anogenital linings) since the involu-
crin promoter has been shown to be active in these sites [37].
Transgene expression could be suppressed by supplementation
with Dox as expected and mice maintained on Dox during
embryonic development and in the post-natal period were normal
at birth, did not have an epidermal barrier defect and survived to
adulthood. Thus, we have developed a Doxycycline–regulated,
inducible transgenic model system that allows us to turn Ets1
expression on or off in the stratified squamous epithelia of mice at
different ages and for different periods of time.
Expression of the Ets1 transgene in adult mice leads to
conspicuous changes in the skin
As noted above, induction of Ets1 expression during embryonic
development leads to neonatal lethality due to a failure to establish
a normal skin barrier function. To overcome this problem, we
suppressed expression of the Ets1 transgene during the embryonic
and postnatal period by maintaining the mice on Dox supple-
mentation. After weaning, Dox was withdrawn allowing transgene
expression (Figure 2A). In adult BT mice, obvious epidermal
alterations became evident within a three- to six-week period after
Dox withdrawal (Figure 2B–D). In particular, BT mice exhibited
patchy hair loss, crusting, scaly skin and open sores covering the
body surface. The skin of the paws and tail was frequently affected.
In addition, BT mice were often very thin and wasted compared to
control littermates, potentially due to difficulties in feeding caused
by changes to the oral cavity, esophagus or forestomach. We noted
some variability in the severity of the phenotype of induced mice,
this might reflect differences in genetic background modifiers as
the pTight-Ets1 transgenic mice were initially derived from a
mixed C3H6C57BL/10 genetic background and subsequently
crossed to FVB/N mice. Alternatively, the differences in
phenotype might reflect variegation in transgene expression or
in the precise timing of transgene induction. The studies described
below assessing histological changes in the skin epidermis were
performed using samples from mice that displayed a visible
phenotype after 3–6 weeks of Ets1 induction.
Histological examination of BT mouse skin revealed striking
hyperplastic and dysplastic alterations when compared to single
transgenic or non-transgenic control mice. The epidermal changes
were most prominent in sections of the affected dorsal trunk, ear
and tail skin (Figure 3A–C). The BT epidermis was dramatically
thickened and hyperkeratotic when compared to control mice and
was composed of predominantly large, pleomorphic cells with
eosinophilic cytoplasm, suggesting that the expanded cell popu-
lation was spinous in nature (acanthosis). Some keratinocytes of
the stratum corneum, though cornified, retained nuclei (paraker-
atosis) indicating a partial block to terminal differentiation. The
alteration of the normal pattern of keratinocyte differentiation was
also apparent from the presence of keratin pearls scattered
throughout the skin. In addition, there was an extensive invasion
of the underlying dermis by the hyperplastic epidermal cells. The
keratinocytes invaded the dermis in the form of large cohesive
masses or thick downgrowths (10–20 cells across) often enclosing
islands of dermal tissues within them. In some cases, enlarged
sebaceous glands and the proximal end of hair follicles formed the
leading edge of the invasive front. As a secondary response to the
epidermal alterations, inflammatory reaction typified by leukocytic
infiltration was also observed. Closer examination showed an
increase in nuclear-to-cytoplasmic ratio, hyperchromatic nuclei
and prominent nucleoli in the keratinocytes (Figure 3D). The
proliferative capacity of the affected epidermis was augmented as
evidenced by increased number of mitotic cells. Interestingly, these
actively dividing cells were not restricted to the proliferative basal
compartment of the epidermis, but were present in the suprabasal
layers too. This suggests that some partially-differentiated
keratinocytes retained or acquired proliferative capability in the
supra-basal layers. A number of these dividing cells had atypical
(tripolar) mitotic spindles, a feature often associated with
transformation (Fig. 3E). Therefore, induction of Ets1 in
differentiating keratinocytes leads to extensive hyperplasia associ-
ated with dysplastic differentiation and downgrowths of chords of
keratinocytes into the dermal compartment.
The keratinocyte differentiation program is disrupted in
epithelia expressing Ets1
The histological analyses described above suggested that the
normal differentiation program of epidermal keratinocytes was
disrupted by expression of Ets1 in the differentiating layers of the
skin. To confirm this result, we stained sections of the dorsal skin of
BT and control mice with antibodies specific for marker proteins
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shown in Figure 4, keratinocytes in the skin of BT mice
demonstrated significant alterations in the expression of these
markers. In particular, expression of cytokeratins typically
localized to the basal layer (K5 and K14) was expanded such
that most of the cells in the epidermis stained positive for these
proteins (Figure 4A and data not shown). In addition, most
suprabasal cells in the epidermis of BT mice expressed K10, a
cytokeratin normally restricted to the spinous layer (Figure 4B). In
contrast, the expression of markers such as loricrin, filaggrin and
involucrin, which are normally restricted to the granular layer of
the epidermis, was decreased (Figure 4C and data not shown).
Figure 2. Ets1 expression results in dramatic alterations to skin homeostasis. (A) Time course of transgene induction. Ets1 expression is
suppressed prenatally and postnatally by feeding the mothers a Dox-containing diet. After weaning at the age of 3 weeks, the Ets1 transgene is
induced by switching the mice to a diet lacking Dox. The phenotype can be observed within 3–6 weeks after diet change. (B–D) Gross phenotype of
several sets of adult WT and BT mice. Arrowheads point to sores, ulcers and crusting on the skin and paws of BT mice. Note that BT mice are
substantially thinner than their wild type littermates.
doi:10.1371/journal.pone.0004179.g002
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data not shown). The reduced expression of loricrin, filaggrin and
involucrin in skin of BT mice likely results in abnormal barrier
function in the affected epidermis. In summary, these studies
indicate that epidermal differentiation of keratinocytes in BT mice
is disrupted with an expansion of keratinocyte populations
expressing early differentiation markers and a reduction in
keratinocyte populations expressing late differentiation markers.
Keratinocytes in epithelia expressing Ets1 undergo
enhanced proliferation and induce the growth of local
blood vessels
As described above, the epidermis of BT mice expressing Ets1
exhibits a dramatic hyperproliferation accompanied by increased
numbers of mitotic figures. Several characteristic marker proteins
are associated with hyper-proliferative epidermis, but are not
normally expressed in the interfollicular epidermis. For instance,
the expression of keratin 6 (K6) is normally limited to the hair
follicles of mice, but is expressed at high levels in interfollicular
epidermis in a variety of hyperplastic and dysplastic conditions.
Consistent with this, there was dramatic upregulation of K6 in the
interfollicular epidermis of BT mice (Figure 5A). Similar
upregulation of K17 was also observed, another keratin that is
characteristically expressed by hyperplastic and dysplastic epider-
mis (data not shown). The enhanced expression of K6 and K17 in
BT epidermis suggested the possibility that there might be altered
expression of proteins involved in regulating the proliferation of
epidermal stem or transit-amplifying cells. One such protein that
has been shown to be critical for epidermal stem cell maintenance
is the transcription factor p63 [38]. Immunostaining demonstrated
that there was a striking increase in the cell population that labeled
with antibody against DN isoform of p63 (the predominant
isoform expressed in skin epidermis) in BT epidermis as compared
to control (Figure 5B). Some of these p63+ cells were found in
suprabasal layers of BT epidermis, whereas they are only found in
the basal layer of wild-type controls. Increased numbers of p63+
cells have also been found in human squamous cell cancers [39,40]
and high levels of p63 expression are correlated with a poor
patient prognosis [41,42].
To more directly test the effects of Ets1 on the proliferation of
epidermal keratinocytes, we stained them with antibodies specific
for PCNA and Ki67 (Figure 5C–D), proteins expressed only in
cells that have entered the cell cycle. The BT epidermis contained
many more PCNA+ and Ki67+ cells than did control epidermis,
confirming enhanced epidermal proliferation in this tissue.
Although the Ets1 transgene was expressed in the more
differentiated layers of the epidermis (upper spinous and granular
layers), the PCNA and Ki67 labeling was mainly associated with
less differentiated layers (basal and lower spinous layers). This
observation suggests that expression of Ets1 may not directly
induce cell proliferation, but rather induce changes in the
differentiation program of the suprabasal cells that cause the
basal cells to undergo a dramatic proliferative response. It is
possible that the increased proliferation may reflect a secondary
response to the compromised barrier function of the epidermis. In
addition, some suprabasal keratinocytes also labeled with anti-
bodies to PCNA and Ki67 indicating a supra-basal proliferation.
While collecting samples of epidermis from BT mice for
processing, we noted increased vascularization of the affected skin
as evidenced by the presence of numerous, large blood vessels in
the dermal tissue (Figure 6A). These vessels were also apparent in
hematoxylin and eosin stained sections of the skin epidermis
Figure 3. Ets1 expression causes hyperplastic and dysplastic changes in the skin epidermis. Microscopic features of the cutaneous
changes in (A) dorsal trunk, (B) ear and (C) tail skin of BT mice upon Ets1 induction show epidermal and sebaceous hyperplasia, hyperkeratosis, and
parakeratosis, keratin pearls (black arrowheads), vascularization, leukocytic infiltration and dermal enclosures within the epidermal downgrowths
(white arrowheads). (D) High power view of the dorsal epidermis demonstrating the presence of several mitotic figures including some in the
suprabasal layers (black arrowheads). Reactive leukocytic infiltration is also evident (asterisk). (E) Further magnification of supra-basal mitoses in
lesions of the dorsal skin in BT mice. Some of the mitoses exhibit abnormal, tripolar mitotic spindles (blue arrowheads).
doi:10.1371/journal.pone.0004179.g003
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marker, PECAM1 (CD31) (Figure 6C). Because the Ets1 transgene
is not expressed in endothelial cells (although the endogenous Ets1
gene is expressed in this cell type), this increased angiogenesis is
likely due to the release of pro-angiogenic molecules from
keratinocytes in the BT epidermis.
Ets1 affects epithelial homeostasis in a reversible and
age-dependent fashion
When BT animals that were severely affected at an early age (4–
12 weeks) were returned to a Dox diet to suppress the transgene
expression, they recovered completely within six weeks and
became indistinguishable from their wild type or single transgenic
littermates (Figure 7A). This overall reversal of skin phenotype was
also clearly apparent upon microscopic examination of biopsies
taken from BT mice before and after Dox rescue (Figure 7B).
Within 6 weeks of turning the expression of HA-Ets1 transgene off,
the epidermis regressed back to its wild type appearance, but for a
residual sebaceous hyperplasia and some dermal fibrosis.
The studies described above were performed on bi-transgenic
mice at an early age (4–12 weeks). To test the effects of Ets1
induction in older animals, we withdrew Dox supplementation
from animals that were older than six months of age. The animals
that underwent a late induction presented with a milder phenotype
including minimal hyperplasia and focal hair loss (Figure 7C).
Thus, there is an age-dependent severity of the phenotype
observed.
Re-induction of the Ets1 transgene leads to localized
lesions
To determine whether repeat induction of the transgene would
result in a more severe phenotype, we induced young adult BT
mice, followed by transgene suppression (by Dox supplementation)
and then reinduction at a later age (Figure 8A). The mice chosen
for these analyses had a severe visible phenotype in the first
induction within a short period, but surprisingly exhibited a more
localized phenotype in the second induction only after an
extended period of induction (4–7 months). The re-induced mice
developed discrete papillomatous or deep ulcerative lesions often
with a distinct crateriform appearance, whereas the bulk of the
Figure 4. Ets1 expression disrupts the normal differentiation pattern of the skin epidermis. Immunofluorescent staining of epidermal
differentiation markers on dorsal skin of induced Ets1 BT mice and littermate wild type mice. Each section was stained with antibodies to b4- integrin
to mark the position of the basement membrane and with DAPI to detect nuclei. Epidermal differentiation was assessed by staining for (A) the basal
layer marker keratin 14 (K14), (B) the spinous layer marker keratin 10 (K10) and (C) the granular layer marker loricrin (Lor). (D) Western blot analysiso f
dorsal skin extracts to confirm results obtained in immunofluorescence. GAPDH serves as a loading control for Western blots.
doi:10.1371/journal.pone.0004179.g004
Figure 5. Ets1 expression induces hyperproliferation of the
skin epidermis. Immunostaining for epidermal hyperplasia with
antibodies to specific markers found in hyperplastic tissues. (A) Staining
with anti-keratin 6 (K6) (counterstained with DAPI to detect nuclei). (B)
Staining with anti-DNp63 (counterstained with nuclear fast red (NFR)).
(C) Staining with anti-Ki67 (counterstained with hematoxylin). (D)
Staining with anti-PCNA (counterstained with anti-K14). Note that the
proliferating cells are located predominantly in the basal layer in both
BT and control samples.
doi:10.1371/journal.pone.0004179.g005
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(B) Hematoxylin and eosin stained sections of dorsal skin from wild type and BT mice. Note the presence of increased numbers of blood vessels in the
dermal compartment of the BT sample (black arrowheads). (C) PECAM-1 (green) staining of skin samples from wild type and BT skin. Sections were
stained with antibodies to keratin 14 (K14, red) to reveal epidermal keratinocytes.
doi:10.1371/journal.pone.0004179.g006
Figure 7. The Ets1 induced phenotype is reversible and age-dependent. (A) Phenotype of BT and control mice at the end of a 3–6 week
induction period and again after 6 weeks of transgene suppression on a Dox diet. Note that BT mice appear completely normal after six weeks of
rescue. (B) Skin samples taken from BT and control mice at the height of the Ets1 induced phenotype and again after transgene suppression. (C)
Comparison of the phenotype of BT mice that were induced for the first time at a young age (early induction) or a late age (late induction). Note the
more severe phenotype evident in the early induction.
doi:10.1371/journal.pone.0004179.g007
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ination of biopsies obtained from these lesions revealed the
presence of hyperproliferation, dysplasia and deep downgrowths
similar to that seen in the primary induction (Figure 8C). Staining
for the basement membrane component laminin demonstrated
that in some samples there were regions of basement membrane
discontinuity (Figure S2). Examination of the differentiation profile
of re-induced lesions indicated that they shared properties seen in
the epidermis of mice that had undergone an early induction, i.e.,
they exhibited greatly enhanced proliferation and a partial block
to terminal differentiation (Figure S3). Overall, the lesions arising
in mice that had undergone secondary induction were less
extensive, but potentially more invasive as demonstrated by
basement membrane discontinuities.
Ets1 expression upregulates a panel of genes involved in
tumor growth and invasion, including MMP13
To understand the molecular mechanisms that drive the
dysplastic changes in the Ets1 BT animals, we analyzed the
expression levels of potential Ets1 target genes. These target genes
were chosen based on prior studies demonstrating that they were
regulated by Ets1 or because they play a critical role in cellular
transformation, epithelial-mesenchymal transition (EMT), cell
cycle regulation, apoptosis or angiogenesis. For this purpose, we
isolated RNA from skin samples of affected BT animals as well as
control animals and performed real-time RT-PCR. These analyses
allowed us to identify a number of genes whose expression was
upregulated in BT epidermis as compared to wild-type or single-
transgenic epidermis. The results of these analyses are summarized
in Table 1. We detected increased expression of several of the
target genes examined including those that are involved in cellular
transformation such as Myc and AP-1 proteins (including Junb,
Jun (c-Jun) and Fos), cell cycle regulators (including Cdkn1a (p21)
and Cdkn2a (p16)) and the anti-apoptotic protein Bcl2l1 (Bcl-xL).
In addition to these genes, we also examined a panel of genes that
are involved in invasive processes, since the downgrowth of
keratinocyte fronts into the dermis was a common feature in all the
affected stratified epithelia. Several matrix metallo-proteases
(MMPs) including collagenases (MMPs 8 and 13), gelatinase
(MMP 9), stromelysins (MMPs 11 and 12), elastase (MMP12) and
membrane associated MMPs (MMP 14 and 16) as well as their
natural inhibitor Timp-1 were upregulated in BT samples
(Table 1). Of the upregulated target genes, MMP13 was the most
dramatically induced gene in Ets1 BT mice.
Figure 8. Reinduction of Ets1 in older mice leads to a less severe phenotype. (A) Schematic representation of a typical time course for the
re-induction studies. Some BT mice underwent transgene induction at an early age (4–6 weeks) and were then rescued by restoring the Dox diet to
suppress transgene expression. The same mice were later reinduced by withdrawing Dox supplementation for an extended time course. After
prolonged transgene induction, these re-induced mice developed discrete lesions (papillomatous or ulcerative, white arrows). (B) Hematoxylin and
eosin stained sections below the time course indicate typical epidermal morphology at each stage of the induction process. (C) Trichrome staining of
the lesions obtained from reinduced BT mice demonstrates downgrowths into the dermis. Boxed areas show regions of thin chords of invading
keratinocytes.
doi:10.1371/journal.pone.0004179.g008
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cleave native, fibrillar collagens including Type IV collagen, a
component of epithelial basement membranes [43]. Expression of
MMP13 is very restricted in normal tissues and is not found in skin
keratinocytes, except under conditions of wound healing, dysplasia
or neoplasia [44,45,46,47,48]. Moreover, MMP13 expression is
considered to be a poor prognostic indicator in SCC [49,50].
Based on these observations as well as the fact that MMP13 was
the most highly-upregulated gene among those we tested, we
focused our further analyses on this putative Ets1 target.
We performed immunostaining for MMP13 in BT and control
mouse skin and found that MMP13 was highly expressed in the
BT skin, while there was no staining in the control samples
(Figure 9A). This is in agreement with the real time PCR data and
also confirms that upregulation of MMP13 is seen in the
keratinocyte compartment (although some staining of the dermal
compartment was also detected). Expression of MMP13 was
particularly evident in the invasive front formed by the proximal
portions of hair follicles and sebaceous glands and in the
cytoplasmic compartments of hyperplastic keratinocytes. Upregu-
lation of MMP13 expression was confirmed by Western blotting
(Figure 9B).
The MMP13 promoter contains three PEA3 motifs (PEA3
sequences are potential Ets binding motifs) and Ets1 has already
been shown to bind to one of these sequences by EMSA analysis
[16,48]. These observations suggest that MMP13 is likely to be a
direct target of Ets1. To confirm that Ets1 can transactivate the
MMP13 promoter, we co-transfected Ets1 and luciferase reporter
gene constructs harboring various lengths of MMP13 promoter
into a mouse keratinocyte cell line. The reporter gene constructs
chosen for these studies have been previously described [48] and
include a 660 bp fragment of the mouse MMP13 promoter fused
to luciferase (p660) as well as several MMP13 promoter deletions:
a 391 bp fragment (p391), a 91 bp fragment (p91) and a 66 bp
fragment (p66). Ets1 dramatically transactivated both the 660 bp
and 391 bp MMP13 promoter constructs by approximately 30-
fold in these cells (Figure 9C), suggesting that the relevant
regulatory elements needed for Ets1 transactivation were con-
tained within the first 391 bp of the promoter. In contrast, Ets1
was significantly less effective in transactivating the 91 and 66 bp
MMP13 promoters (2–3 fold stimulation of activity by Ets1).
These observations suggest that the important Ets1 responsive
elements are localized between 291 and 2391 bp of the MMP13
promoter. This was confirmed by testing the activity of a mutant
form of the p391 promoter (p391 del (PEA)) that contains a short
deletion in one of the PEA3 motifs (the 2122 bp Ets binding site)
(Figure 9C). The deletion construct exhibited responsiveness to
Ets1 that was very similar to that of the p91 and p66 promoters.
Thus, the Ets1 binding site at 2122 bp of the murine MMP13
promoter is essential for maximal transactivation capacity of Ets1.
To confirm that Ets1 can associate with the MMP13 promoter
in vivo, we performed chromatin immuno-precipitation (ChIP)
experiments on dorsal mouse skin epidermis derived from BT and
wild type mice using antibodies specific for Ets1 and for the HA-
tag on the Ets1 transgene. In wild type mice, the anti-Ets1
antibody precipitated the MMP13 promoter, whereas the HA
antibody did not (Figure 9D). In the BT sample, both anti-Ets1
and anti-HA antibodies pulled down the MMP13 promoter.
These observations suggest that Ets1 is associated with the
MMP13 promoter region in both wild type and BT mice,
although the MMP13 gene is only expressed in the BT animals.
Discussion
The Ets1 transcription factor regulates many important cellular
processes including cellular growth and differentiation [51]. High
level expression of the Ets1 oncogene has been linked previously to
tumor progression, invasion and metastasis in squamous cell
Table 1. Gene expression profiles in WT versus BT mice.
Gene Name Common Name
Fold change in
expression
Flt1 VEGF-R1 2.4
Kdr VEGF-R2 1.67
Tie1 Tie1 0.71
Tek Tie2 0.57
Angpt2 Angiopoietin-2 1.67
Nos3 eNOS 2
Itgav av-Integrin 1.36
Cdh1 E-Cadherin 0.85
Cdh5 VE-Cadherin 0.81
Cdkn1a p21 4.5
Cdkn2a p16 6.78
Cdc2l6 CDK11 0.87
Trp53 p53 1.2
Mdm2 Mdm2 1.23
Jun c-jun 22.0
Junb JunB 7.26
Fos c-fos 9.0
Myc C-myc 2.24
Ddit3 GADD153 1.02
Lmo2 Lmo2 0.83
Vim Vimentin 0.74
Bcl2l1 Bcl-XL 2.25
Bcl2 Bcl-2 0.6
Casp1 Caspase-1 1.52
Fasl Fas Ligand 0.08
Tnf TNF-a 5.5
Pthlh PTHrP 0.59
Met c-met 0.95
Plau uPA 0.64
Serpinb5 Maspin 1.39
Mmp2 Gelatinase A 4.2
Mmp3 Stromelysin-1 3.8
Mmp8 Collagenase-2 151.2
Mmp9 Gelatinase B 43.1
Mmp10 Stromelysin-2 7.4
Mmp11 Stromelysin-3 41.6
Mmp12 Macrophage metalloelastase 13.8
Mmp13 Collagenase-3 770
Mmp14 Membrane type 1-MMP 2.3
Mmp15 Membrane type 2-MMP 0.9
Mmp16 Membrane type 3-MMP 8.0
Mmp17 Membrane type 4-MMP 0.5
Mmp19 Mmp19 0.9
Timp1 Timp1 5.3
doi:10.1371/journal.pone.0004179.t001
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PLoS ONE | www.plosone.org 9 January 2009 | Volume 4 | Issue 1 | e4179Figure 9. Ets1 expression induces upregulation of MMP13. (A) Immuno-histochemical staining for MMP13 (brown) in the skin of wild-type
and BT mice. Sections were counterstained with hematoxylin. Note expression of MMP13 in the invading front (hair follicles and sebaceous glands)
and in hyperplastic keratinocytes in the BT sample. (B) Western blot for MMP13 expression in skin extracts of wild-type and BT mice. GAPDH is a
loading control. (C) Luciferase assays using different lengths of the mouse MMP13 promoter (MMP13) or an empty vector lacking a promoter (pGL3B)
transfected into mouse MK keratinocytes. The MMP13 promoter was transfected with an expression vector driving HA-tagged mouse Ets1 (pCMV-HA-
Ets1) or with a control empty vector (pCMV-HA). Results represent the fold induction of luciferase activity in cells transfected with the Ets1 expression
vector as compared to empty vector and have been corrected for the activity of the internal control plasmid (pCMVb-gal). Arrows in the p391
construct indicate the positions of primers used in part D for chromatin immunoprecipitation. (D) Chromatin immunoprecipitation assays to detect
association of Ets1 with the endogenous MMP13 promoter in wild-type and BT mice. Antibodies used for immunoprecipitation include anti-Ets1 or a
control rabbit IgG and anti-HA or a control rat IgG. Immunoprecipitated chromatin was amplified with primers specific for the mouse MMP13
promoter or for the GAPDH gene. Results represent relative concentrations of products amplified by qPCR.
doi:10.1371/journal.pone.0004179.g009
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with invasion and metastasis is likely to reflect the ability of Ets1 to
control the expression of MMP enzymes that function to degrade
extracellular matrix components. However, Ets1 is also thought to
regulate genes involved in cellular proliferation and survival,
suggesting that it might also play a role in the earlier stages of
carcinogenesis. To determine the precise biological role of Ets1 in
tumor formation and progression, we developed a transgenic
mouse model that allows us to induce the expression of an Ets1
transgene in a spatially and temporally-restricted manner.
Ets1 drives dysplastic changes in stratified squamous
epithelium
Using an inducible transgenic model system, we have
demonstrated that expression of the Ets1 oncogene in the
differentiating layers of mouse stratified squamous epithelium
leads to a dramatic epithelial phenotype, visibly apparent by the
appearance of crusting, flaky skin and open sores. Dysregulated
Ets1 expression induced a wide spectrum of progressive prema-
lignant changes such as those induced by chemical carcinogens,
activated oncogenes, or loss of tumor suppressors in well-
established mouse models of squamous cell carcinogenesis. The
dysplastic phenotype includes increased keratinocyte proliferation,
decreased keratinocyte terminal differentiation and the presence of
mitoses (some of which were abnormal) in the suprabasal layers of
the epidermis. The dermal responses include increased vascular-
ization and leukocytic infiltration.
The inhibition of expression of terminal differentiation markers
such as involucrin and loricin caused by Ets1 induction likely leads
to a severe defect in epidermal barrier formation. Indeed, the
phenotype induced by Ets1 transgene expression is similar to that
seen in the adult skin of other strains of mice reported to develop
barrier defects (e.g., transglutaminase-1 deficient skin or matrip-
tase over-expressing skin) [52,53]. Like these strains, Ets1 BT mice
develop extensive skin hyperplasia, abnormal terminal differenti-
ation and hyperkeratosis. However, Ets1 BT mice also develop
deep down-growths of the epidermis into the dermal compart-
ment, which have not been reported in these other strains. These
down-growths may be related to the high expression of several
MMP family members by Ets1 BT mice. The defect in epidermal
barrier function in the BT mice could trigger a hyper-proliferative
state as an attempt to restore normal barrier function. This would
be consistent with the observation that the majority of Ki67+ and
PCNA+ cells are found in the basal layer rather than the
suprabasal layers, where Ets1 is expressed. In contrast, dysplastic
changes including abnormal terminal differentiation and the
presence of abnormal mitoses were associated with the supra-
basal layers where the Ets1 transgene is expressed, suggesting a
direct effect of Ets1 on these parameters. Together these results
indicate that Ets1 may have an early role in cancer progression in
addition to its more established role in tumor metastasis. Despite
the extensive alterations in cutaneous architecture, the molecular
and the consequent structural changes in the inter-follicular
epidermis are completely reversible when Ets1 expression is
suppressed by re-instating Dox treatment. This reversal of the
dysplastic phenotype is reminiscent of human SCC precursor
lesions such as actinic keratosis and Bowen’s disease, which can
undergo spontaneous regression.
Importantly, these changes in the epidermis occur in the
absence of any tumor promoting chemicals or UV radiation.
Moreover, the fact that the entire skin epidermis is affected (in
young animals), that the phenotype develops very rapidly after
induction (within 3–6 weeks) and that the phenotype is completely
reversible suggest that additional genetic hits to other oncogenes or
tumor suppressor genes are not required. Hence, over-expression
of Ets1 alone is sufficient to cause severe epidermal dysplasia.
The dysplastic phenotype induced by Ets1 expression was
stronger in animals induced at a young age (less than 3 months of
age). The reason for this age-dependent affect is not yet clear,
however, it may potentially be due to lower levels of expression of
the transgene in older animals or to changes in the physiology of
the epidermis between young and old mice. When we induced BT
mice at a young age followed by suppression of Ets1 expression
and re-induction at an older age, we noted that the phenotype in
the second induction was also overall weaker. This weaker
phenotype allowed a longer induction period after which discrete
ulcerative or papillomatous lesions arose in these re-induced mice.
The appearance of discrete lesions in an otherwise weakly affected
epithelium and the need for a long induction period strongly
suggests that additional genetic hits must occur in these tissues to
promote lesion formation. Alternatively, it is possible that
stochastic down-regulation of the Ets1 transgene expression via
epigenetic changes could result in the expression of the transgene
in discrete patches in the adult.
Cells already committed to differentiation are targets of
Ets1 action
Oncogenic mutations in stem cells have been implicated in the
development of skin tumors [54,55]. Epidermal stem cells are
thought to reside in the hair follicle bulge region as well as being
scattered throughout the basal layer of the interfollicular
epidermis. Interestingly, in our transgenic model system, Ets1
overexpression is not targeted to the epidermal stem cells, but
rather to keratinocytes that have already committed to differen-
tiation. This is in contrast to most other transgenic models of SCC,
where transgene expression is targeted to the basal proliferative
layer (e.g., oncogenic Ras, [56]). Indeed, when the Ets1 transgene
is expressed in the basal compartment of the epidermis (including
epidermal stem cells) using a keratin 5 (K5) tTA transgenic line, no
phenotype is evident in adult BT mice (our unpublished data).
Interestingly expression of c-myc in the differentiated layers of the
skin also results in hyperproliferation and formation of papillomas
[57], whereas targeting c-myc to the basal proliferative layer does
not promote keratinocyte proliferation or papilloma formation
[58]. Thus, Ets1 and c-myc appear to share a property that allows
them to induce pre-neoplastic changes in epidermal cells that have
already committed to terminal differentiation.
Ets1 regulates the expression of a variety of genes
implicated in tumorigenesis
Mice expressing the Ets1 transgene exhibit upregulation of
many known and potential Ets1 target genes involved in
proliferation, survival and apoptosis. These genes include
proteases, cell cycle regulators, anti-apoptotic proteins and
transcription factors. The phenotype arising in the induced BT
mice likely reflects the combined action of several of these genes.
For instance, upregulation of Myc in the suprabasal epidermal
layers has been shown to lead to a similar epidermal phenotype
characterized by reversible epidermal papillomatosis and seba-
ceous gland enlargement [57,59]. Thus, upregulation of Myc
could contribute to multiple aspects of the dysplastic phenotype
observed in Ets1 BT mice. Another group of proteins that could
potentially contribute to Ets1 induced dysplastic epidermal
changes is the AP-1 family. AP-1 proteins control transcriptional
activation or suppression of a number of genes involved in
proliferation, differentiation and transformation. Of the AP-1
proteins that are upregulated in Ets1 BT skin, Jun and Fos have
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Moreover, AP-1 transcription factors along with Ets proteins can
exert a combinatorial control of expression of several genes that
include importantly metalloproteinases.
Matrix metalloproteinases appear to be chief effectors of Ets1
induced epithelial alterations [51]. Several MMPs have been shown
to be direct targets of Ets proteins and are often co-regulated by AP-
1 proteins. Various classes of metalloproteinases such as collage-
nases (MMPs 8 and 13), gelatinases (MMPs 2 and 9), stromelysins
(MMPs 3, 10 and 11), metalloelastase (MMP12) and membrane-
type MMPs (MMPs 14 and 16) are upregulated in Ets1 BT skin.
This suggests that several biological processes that accompany Ets1
induced dysplasia could be attributed to the function of MMPs. We
focused our attention on the most highly upregulated target gene,
matrix metalloprotease 13 (MMP13). We demonstrate that Ets1
directly regulates expression of the MMP13 gene and can be
detected at the promoter region. Interestingly, Ets1 was associated
with the promoter region of MMP13 in both BT and control skin
samples. This may suggest that Ets1 is constitutively associated with
the promoter of this gene, but is inactive unless it becomes
phosphorylated or that it requires the recruitment of an inducible
co-factor to mediate full induction of the gene. -
MMP enzymes including MMP13 are best known for their
ability to degrade a wide variety of extracellular matrix substrates
including collagen, fibronectin, laminin, perlecan, tenascin C and
fibrillin [43,62]. By degrading extracellular matrix components,
MMPs can promote the invasion of cells into the surrounding
tissues. Moreover, degradation of extracellular matrix may lead to
the release of latent growth factors and angiogenic factors,
promoting tumor cell proliferation. Furthermore, numerous
studies have detected degradation of key epithelial adhesion
proteins, such as E-cadherin and desmogleins, by members of the
MMP family [63,64,65,66,67,68], suggesting that MMP activity
can result in diminished keratinocyte adhesion to neighboring
cells. Together these activities of MMP proteins can promote
keratinocyte proliferation, migration and invasion.
-MMP proteins have the ability to promote dysplastic changes in
tissues, even when they are expressed alone in the absence of other
genetic changes or tumor inducing chemicals or UV radia-
tion[63,69,70,71,72]. In addition, over-expression of matriptase, a
protease that has been suggested to be an upstream activator of
MMP3 [73], induces squamous cell carcinoma in the skin [52].
Thus, expression or activation of numerous MMP proteins can
promote hyperplastic and neoplastic changes in epithelial tissues,
supporting the idea that overexpressionof MMPs may be important
to the development of pre-neoplastic and neoplastic alterations in
Ets1 BT mice. It is likely that MMPs cooperate with other genes
induced by Ets1 overexpression (such as myc and AP-1 family
members) to promote the dysplastic changes.
The role of Ets1 in keratinocyte differentiation and future
prospects
In addition, to promoting proliferation and invasion of skin
keratinocytes, Ets1 expression also blocked their terminal
differentiation program. The block to terminal differentiation
likely results in impaired barrier formation in the skin and is likely
the cause of perinatal mortality for Ets1 BT mice that undergo
transgene induction during embryonic development. The effect of
Ets1 in blocking terminal differentiation may arise from its ability
to interfere with the transcriptional programs that drive the
differentiation process. For instance, we have recently shown that
Ets1 physically interacts with the transcription factor Blimp-1 to
inhibit its function [74]. Blimp-1 is important for the final
differentiation step of keratinocytes from the granular layer to the
cornified layer [75]. By interfering with Blimp-1 or other
transcription factors, Ets1 may prevent their function and thereby
block the terminal differentiation of the epidermis.
In summary, using an inducible transgenic mouse model, we
have demonstrated that expression of the Ets1 transcription factor
leads to a dramatic hyperplastic and dysplastic phenotype in skin
epithelium of young mice in the apparent absence of other genetic
lesions. This represents the first report that Ets1 can play a major
role in the early stages of the carcinogenic process. Together, these
studies extend our understanding of the role of Ets1 in squamous
cell tumors and suggest mechanisms by which Ets1 can promote
cellular transformation and tumor progression. Our data described
here strongly suggest that in a variety of human carcinomas, over-
expression of Ets1 may not just be a prognostic indicator, but play
an important causal role that can be exploited for targeted
therapy. In the future, our transgenic model system can be used to
induce Ets1 in any tissue or cell type by utilizing the appropriate
tetracycline-transactivator lines, and hence will prove useful in
understanding the role of Ets1 in regulating development,
differentiation and oncogenic conversion in a variety of tissues.
Materials and Methods
Ethics Statement
All mouse experiments were approved by the State University of
New York at Buffalo IACUC committee and carried out in
accordance with relevant national guidelines.
Generation and analysis of transgenic mice
The Ets1 doxycycline inducible construct was generated by
cloning full length mouse Ets1 cDNA with a 59 HA tag into the
pTRE-Tight plasmid (BD Biosciences Clontech). The inducible
Ets1 construct was micro-injected into fertilized mouse oocytes
derived from a mixed genetic background (C3Hf/HeR-
os6C57BL/10 Rospd). Six transgenic lines were generated in
these initial injections. The following primers were used to
genotype the transgenic mice: forward (59-ATAGTTGT-
GACCGCCTCACC -39) and reverse (59- GGGAGGTGTGG-
GAGGTTTT-39). The founders were then crossed to INV-tTA
mice (a kind gift from Dr. Julia Segre, National Human Genome
Research Institute, Bethesda) to determine expression of the
transgene. Inv-tTA mice were on an FVB/N genetic background
and BT mice derived from these crosses were subsequently
backcrossed to FVB/N mice for several generations.
Antibodies Used
The following primary antibodies were used for Western
blotting, immunofluorescence and/or immunohistochemistry: rat
monoclonal anti-HA (clone 3F10, Roche Applied Sciences), rabbit
polyclonal anti-Ets1 (N-276, Santa Cruz Biotechnology), mouse
monoclonal anti-GAPDH (clone 6C5, Chemicon International),
goat polyclonal anti-MMP13 (W-16, Santa Cruz Biotechnology),
mouse monoclonal anti-Ki67 (NCL-Ki67p, Novocastra), rat
monoclonal anti-b4 integrin (CD104, clone 346-11A, BD
Biosciences), rat monoclonal anti-PECAM1 (CD31, clone MEC-
13.3, BD Biosciences), rabbit polyclonal anti-laminin I
(CL54851AP, Cedarlane Laboratories) and mouse monoclonal
anti-PCNA (clone PC10, Dakocytomation). A rabbit polyclonal
anti-DNp63 antibody (RR-14, developed in the laboratory of Dr.
Satrajit Sinha) was also used. In addition, several polyclonal rabbit
primary antibodies specific for keratinocyte marker proteins
(keratin 1, keratin 5, keratin 6, keratin 10, keratin 14, involucrin
and loricrin) were generous gifts of Dr. Julia Segre (National
Human Genome Research Institute, National Institutes of
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was a gift of Dr. Pierre Coloumbe (Johns Hopkins University
School of Medicine).
Western blotting
Whole tissue lysates were prepared using Laemmli sample
buffer (BioRad Laboratories) or RIPA buffer from BT and control
mouse dorsal skins. Equal amounts of lysates were loaded on 10%
SDS-polyacrylamide gels and transferred to Immun-Blot PVDF
membrane (BioRad Laboratories). After blocking, the membranes
were incubated in the specific primary antibodies: anti-HA
(1:2000), anti-Ets1 (1:1000), anti-GAPDH (1:10000) or anti-
MMP13 (1:200). Antibodies against keratinocyte markers –
keratin10, keratin14, involucrin and loricrin -were used at a
dilution of 1:5000. After washing, the membranes were incubated
with specific horseradish peroxidase (HRP) conjugated secondary
antibodies at 1:20,000 dilution. Specific bands were detected by
chemiluminescence (KPL or Pierce).
Immunohistochemistry and Immunofluorescence
For histological analyses, skin samples from various regions of
the body were fixed in 4% paraformaldehyde and embedded in
paraffin. 4-mm thick sections were then stained with hematoxylin
and eosin or Masson’s trichrome reagent. For immunohistochem-
istry, 4-mm thick skin sections were deparaffinized and subjected to
antigen retrieval by heating. The sections were then immuno-
stained with specific primary antibodies - anti-HA (1:300), anti-
DNp63 (1:300), anti-Ki67 (1:200), anti-Ets1 (1:150), anti-MMP13
(1:40), anti-keratin 1 (1:500), anti-keratin 5 (1:500), anti-keratin 6
(1:500), anti-involucrin (1:500), and anti-loricrin (1:500) - using the
Vectastain ABC kit (Vector labs). Diaminobenzidine (DAB) or
Vector Blue (Vector Labs) was used as the enzyme substrate and
counter-stained with hematoxylin or Nuclear Fast Red (NFR).
For immunofluorescence, 5-mm thick OCT embedded fresh
frozen sections were fixed in ice-cold methanol. After blocking, the
sections were incubated with anti-keratin6, anti-keratin10, anti-
keratin14, anti-loricrin, anti-b4 Integrin or anti-PECAM1 antibod-
ies at 1:500 dilution or with anti-Laminin or anti-PCNA antibodies
at 1:100 dilution. The sections were then washed and incubated
with Alexa-Fluor 568 coupled anti-rabbit IgG (1:750), Alexa-Fluor
488 coupled anti-rat IgG (1:500) or FITC coupled anti-mouse IgG
(1:500) antibodiesandcounterstainedwith DAPI (49,6-diamidino-2-
phenylindole). The immunostained sections were mounted in 80%
glycerol in PBS, viewed and photographed at room temperature
with an Axiophot Zeiss microscope, equipped with a Hamamatsu
ORCA-ER camera linked to SPOT software for image capture.
The contrast and brightness of the images were adjusted using the
Adobe Photoshop and ImageJ software.
Quantitative PCR Analysis
Total RNAs were isolated using Trizol (Invitrogen) and treated
with DNAse I Turbo (Ambion) to remove genomic DNA
contamination. Equivalent quantities of RNA were reverse
transcribed using iScript kit (BioRad) and real-time PCR was
performed in the ICycler system (BioRad), using iQ SYBR green
supermix (BioRad) and gene specific primers. Differences between
BT samples and controls were normalized to expression of the
ubiquitously-expressed gene b2-microglobulin and determined
using the 2
2DCt method.
Reporter gene assays
For transient transfections, mouse MK1 keratinocyte cells were
plated at a density of 1.2610
5 cells/well in 6 well plates and were
transfected using Optifect (Invitrogen) or Fugene 6 reagent (Roche
Diagnostics) at a density of 40% according to the manufacturer’s
instructions. The cells were transfected with 0.5 mg/well of each of
the following plasmids: pGL3-basic or various lengths of MMP13
promoter cloned into the pGL3-basic plasmid: 2660 bp,
2391 bp, 2391 bp DPEA, 291 bp, and 266 bp relative to
transcription start site (generous gifts from Dr. Jeffrey M.
Davidson, Vanderbilt University, Nashville and Dr. Keith Kirk-
wood, University of Michigan, Ann Arbor). Cells were also co-
transfected with the empty pCMV-HA vector (Clontech) or
pCMV-HA-Ets1 (containing an HA-tagged version of mouse Ets1)
and with pCMV-LacZ (0.25 mg/well) as an internal control. Cells
were harvested 48 hours post transfection in Reporter Lysis buffer
(Promega) and luciferase assays were performed. b-galactosidase
values were measured using the Galacton Plus kit (Applied
Biosystems). The luciferase values were normalized to b-galacto-
sidase levels to correct for transfection efficiency. Reporter assays
were performed in duplicates of at least three independent
experiments and expressed as the means6S.D.
Chromatin Immunoprecipitation
Dorsal skins from wild-type and BT adult mice were de-epilated
and treated with ammonium thiocyanate solution to separate the
epidermis from the underlying dermis. The epidermal cells were
disaggregated and fixed in 1% formaldehyde for 15 mins at RT.
After washing, the cells were sonicated to fragment chromatin.
The chromatin was then immunoprecipitated using the Chroma-
tin Immunoprecipitation Assay kit (Upstate Biotechnology) and
the following antibodies: anti-HA, anti-Ets1, isotype-control rat
IgG or isotype control rabbit IgG. Immunoprecipitated samples
were analyzed by PCR using primers designed to the minimal
promoter of mouse MMP13: forward 59 TCCATTTCCCTCA-
GATTCTGCCAC-39 and reverse 59-CAGCAGTGCCTG-
GAGTCTCT-39. As a control, PCR was also performed using
primers that recognize the minimal promoter of mouse GAPDH.
Online Supplemental Material
Hematoxylin and eosin staining and immuno-staining results
presented in the online supplementary figures were collected using
the same techniques and reagents as described above.
Supporting Information
Figure S1 Ets1 is not essential for epidermal development. (A)
Ets1 knockout mouse demonstrating areas of white spotting (non-
pigmented hair and skin) (B) Hematoxylin and eosin stained
section of adult dorsal skin from an Ets1 knockout mouse, showing
normal histology. C. High power view of boxed area in B.
Found at: doi:10.1371/journal.pone.0004179.s001 (1.48 MB TIF)
Figure S2 Loss of basement membrane integrity in re-induced
lesions. Immunostaining for laminin I (red) shows breaks in
basement membrane (arrows) in cutaneous lesions of the re-
induced BT mice. Tissues are counterstained with K14 (to mark
keratinocytes) and DAPI (to mark nuclei).
Found at: doi:10.1371/journal.pone.0004179.s002 (1.87 MB TIF)
Figure S3 Enhanced keratinocyte proliferation and block to
terminal differentiation in the re-induced tumors. Detection of
stage-specific keratinocyte differentiation and proliferation mark-
ers in re-induced lesions by immunostaining (DAB staining,
brown). The lesions display enhanced expression of early (keratin
5, K5) and intermediate differentiation (keratin 1, K1 and
involucrin, inv) markers and decreased expression of the late
differentiation marker loricrin (Lor). There is also enhanced
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Ki67, and DeltaNp63.
Found at: doi:10.1371/journal.pone.0004179.s003 (1.96 MB TIF)
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